We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Pall, Kaneka Enter Agreement

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

KANEKA KanCapA enables the high productivity affinity capture of monoclonal antibodies and related biomolecules using a proprietary alkali stable rPrA ligand. The sorbent will be supplied in a range of pre-packed columns and high throughput screening tools, as well as in bulk for use in the industry leading Resolute® AutoPak columns.

Key features of KANEKA KanCapA, which is manufactured in a State-of-the Art facility in Japan, are its high dynamic binding capacity, good flow performance and optimal alkali stability for reuse, key attributes for both batch and continuous chromatography.

The introduction of KANEKA KanCapA expands the portfolio of continuous bioprocessing and chromatography products offered by Pall, which recently announced the acquisition of the BioSMB® multicolumn continuous chromatography platform from Tarpon Biosystems, and the licensing of the Acoustic Wave Separation (AWS) technology from FloDesign Sonics. "KANEKA KanCapA provides the key chromatographic step required in a typical MAb purification process and integrates with our existing cation exchange sorbents and Mustang® Q membrane chromatography,” said Michael Egholm, Vice President and General Manager of Pall Biopharmaceuticals. "Our customers will be able to go directly from CHO cell culture in the bioreactor  through continuous clarification using AWS and STAX™ depth filtration products to provide a continuous feed stream for direct integration with the BioSMB platform.”

Pall plans to introduce a single-use product line including AWS and BioSMB technologies for the purification of biological from cell culture at both bench scale and GMP scale to match pilot and production bioreactor volumes, with predictable and reproducible performance over a wide range of cell densities. Over the coming months, Pall will engage with industry thought leaders in evaluation of all these technologies and their benefits.